Almac Discovery Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Almac Discovery Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011850
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Almac Discovery Ltd (Almac Discovery), a subsidiary of Almac Group Ltd is a healthcare service provider that discovers and develops drugs for the treatment of cancer. The company develops drugs, small molecule and therapeutic peptide, biomarkers and diagnostic tools. It provides early drug discovery and development services such as target finding, phase I clinical trials, lead optimization, preclinical development and clinical development. Almac Discovery’s pipeline products include ALM201, a microtubule binding agent in Phase 1 for the treatment of solid tumours; ALM301, a allosteric Akt inhibitor; and Wee-1 Inhibitor for the control of cell cycle. The company also conducts research on DNA repair and deubiquitinating enzymes. Almac Discovery is headquartered in Craigavon, the UK.

Almac Discovery Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Almac Discovery Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 10
McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 11
Elasmogen and Almac Discovery Enter into Co-Development Agreement 12
Almac Discovery Enters Into Agreement With Queen’s University Belfast For Drug Discovery 13
Beactica Enters Into Drug Discovery Agreement With Almac Discovery 15
Licensing Agreements 16
Debiopharm International Enters into Licensing Agreement with Almac Discovery 16
Genentech Enters into Licensing Agreement with Almac Discovery 17
Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 18
Almac Discovery Ltd – Key Competitors 19
Almac Discovery Ltd – Key Employees 20
Almac Discovery Ltd – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Product News 22
Dec 04, 2017: Almac Discovery Publishes USP7 Inhibitors From UbiPlex Platform 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Almac Discovery Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Almac Discovery Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Almac Discovery Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 10
McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 11
Elasmogen and Almac Discovery Enter into Co-Development Agreement 12
Almac Discovery Enters Into Agreement With Queen’s University Belfast For Drug Discovery 13
Beactica Enters Into Drug Discovery Agreement With Almac Discovery 15
Debiopharm International Enters into Licensing Agreement with Almac Discovery 16
Genentech Enters into Licensing Agreement with Almac Discovery 17
Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 18
Almac Discovery Ltd, Key Competitors 19
Almac Discovery Ltd, Key Employees 20

★海外企業調査レポート[Almac Discovery Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pyxus International Inc:企業の戦略・SWOT・財務情報
    Pyxus International Inc - Strategy, SWOT and Corporate Finance Report Summary Pyxus International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Imperial College London-医療機器分野:企業M&A・提携分析
    Summary Imperial College London (Imperial) is a research university that offers educational services. The university provides undergraduate and postgraduate courses. It offers courses in the field of science and technology, agriculture, business, the humanities, and medicine. It conducts clinical tr …
  • Pakistan Water and Power Development Authority:企業の戦略的SWOT分析
    Pakistan Water and Power Development Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Church & Dwight Co Inc:企業の戦略・SWOT・財務情報
    Church & Dwight Co Inc - Strategy, SWOT and Corporate Finance Report Summary Church & Dwight Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Soitec SA (SOI):企業の財務・戦略的SWOT分析
    Soitec SA (SOI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …
  • Yue Yuen Industrial (Holdings) Limited:企業の戦略・SWOT・財務情報
    Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary Yue Yuen Industrial (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Australian Vintage Limited:企業の戦略・SWOT・財務情報
    Australian Vintage Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Vintage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Etihad Aviation Group PJSC:企業の戦略・SWOT・財務情報
    Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report Summary Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Chembond Chemicals Ltd (530871):企業の財務・戦略的SWOT分析
    Chembond Chemicals Ltd (530871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Teva Pharmaceutical Industries Limited:企業の戦略・SWOT・財務情報
    Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Teva Pharmaceutical Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Shri Lakshmi Cotsyn Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Cotsyn Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hannover Ruck SE:企業の戦略・SWOT・財務情報
    Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report Summary Hannover Ruck SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Vestas Wind Systems A/S:企業の戦略・SWOT・財務情報
    Vestas Wind Systems A/S - Strategy, SWOT and Corporate Finance Report Summary Vestas Wind Systems A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Chico’s FAS Inc:企業の戦略・SWOT・財務情報
    Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report Summary Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • PDL Biopharma, Inc.:企業の戦略・SWOT・財務情報
    PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report Summary PDL Biopharma, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • iMedX Inc-医療機器分野:企業M&A・提携分析
    Summary iMedX Inc (iMedX) is a provider of medical document management and health information solutions. The company offers transcription services and coding services. It provides iMedX Express web based platforms and iMedX Mobile with DocAssist applications. iMedX’s transcription services comprise …
  • Babcock Power Inc:企業の戦略的SWOT分析
    Babcock Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Knight Therapeutics Inc (GUD):企業の財務・戦略的SWOT分析
    Summary Knight Therapeutics Inc (Knight Therapeutics) is a specialty pharmaceutical company focused on acquisition, licensing, marketing and distribution of prescription, consumer health products and medical devices. Its consumer health products are used for the treatment of metabolic diseases, derm …
  • Seplat Petroleum Development Company Plc (SEPLAT):企業の財務・戦略的SWOT分析
    Summary Seplat Petroleum Development Company Plc (Seplat) is an independent upstream exploration and production company that offers development and operation of oil and natural gas reserves and production assets. The company produces oil from fileds such as Amukpe, Oben, Okporhuru, Ovhor, Orogho, Sa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆